Search Results
Sep 30, 2025, 08:30 ET Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership
that combat age-related decline. By adding Turn's ERA technology — which leverages six RNA molecules, including four of the Yamanaka transcription factors that can reset cellular age — together with the eTurna RNA lipid nanoparticle (LNP) delivery platform, we are expanding beyond a single Klotho gene
More news about: Klotho Neurosciences, Inc.
Sep 29, 2025, 17:31 ET DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology and Virology | DelveInsight
extension of the ALLIANCE study, after switching from DTG + F/TDF to BIKTARVY following 96 weeks of prior therapy, 95.4% of participants achieved HIV RNA <50 copies/mL, while 86.6% reached HBV DNA <29 IU/mL. Learn more about the DNA synthesis inhibitors @
More news about: DelveInsight Business Research, LLP
Sep 29, 2025, 11:21 ET Contagem regressiva para o verão: é hora de cuidar da pele para chegar com tudo no período de festas e férias
1. Waibel J, Ziegler M, Nguyen TQ, Le JHTD, Qureshi A, Widgerow A, Meckfessel M. Comparative Bulk RNA-Seq Analysis of Poly-l-Lactic Acid Versus Calcium Hydroxylapatite Reveals a Novel, Adipocyte-Mediated Regenerative Mechanism of Action Unique to PLLA.
More news about: Galderma
Sep 29, 2025, 10:18 ET METiS Launches World's First AI-Driven Nano-Delivery Platform NanoForge
AI-driven nano-delivery platform. Dr. Chris Lai, Co-Founder and CEO of METiS, led a team of scientists specializing in AI, platform technology, and RNA R&D to present NanoForge's breakthrough capabilities and its practical applications in therapeutic pipeline development. NanoForge
More news about: METiS TechBio
Sep 29, 2025, 08:30 ET Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies
More news about: Oncolytics Biotech® Inc.
Sep 29, 2025, 05:01 ET Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
industry. Its ability to support diverse modalities—from small molecules and antibodies to emerging therapies such as PROTACs, molecular glues, and RNA-targeting compounds—significantly reduces development timelines and costs for global clients," said Priyanka Jain, senior research analyst at Frost
More news about: Viva Biotech
Sep 29, 2025, 05:00 ET Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
industry. Its ability to support diverse modalities—from small molecules and antibodies to emerging therapies such as PROTACs, molecular glues, and RNA-targeting compounds—significantly reduces development timelines and costs for global clients," said Priyanka Jain, senior research analyst at Frost
More news about: Viva Biotech
Sep 29, 2025, 00:00 ET Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
industry. Its ability to support diverse modalities—from small molecules and antibodies to emerging therapies such as PROTACs, molecular glues, and RNA-targeting compounds—significantly reduces development timelines and costs for global clients," said Priyanka Jain, senior research analyst at Frost &
More news about: Frost & Sullivan
Sep 29, 2025, 00:00 ET Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
industry. Its ability to support diverse modalities—from small molecules and antibodies to emerging therapies such as PROTACs, molecular glues, and RNA-targeting compounds—significantly reduces development timelines and costs for global clients," said Priyanka Jain, senior research analyst at Frost &
More news about: Frost & Sullivan
Sep 26, 2025, 06:30 ET Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications
RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue sectionTechnologies support spatial multiomic analysis and deeper insights for pathology workflowsResearch highlights potential role in clinical utility
More news about: Bio-Techne Corporation
Sep 25, 2025, 16:41 ET GreenLight Biosciences Launches Norroa, the First RNA-Based Treatment for Varroa Mites, Offering New Hope Amid Record Bee Losses
ecosystem balance of the surrounding area, aligning with sustainable agricultural practices." Norroa's active ingredient, vadescana, leverages RNA interference (RNAi), a natural biological process that precisely targets varroa mites and ultimately stops their reproduction. It is part of the
More news about: GreenLight Biosciences
Sep 25, 2025, 08:01 ET Breakthrough T1D, Lupus Research Alliance, and National Multiple Sclerosis Society Award Recipients of First Common Mechanisms of Autoimmunity Insight Award
will study how B cells might be orchestrating the immune system's attacks in multiple sclerosis and type 1 diabetes. Using cutting-edge single-cell RNA sequencing, he will examine which genes are switched on in each B cell, one cell at a time, to begin to piece together the complex chain of events leading
More news about: Lupus Research Alliance
Sep 25, 2025, 08:00 ET Nobel Laureate Headlines Global Discussion in Cell & Gene Therapy in London
Medicine, co-director of the RNA Therapeutics Institute at the University of Massachusetts Medical School, is best known for his co-discovery of RNA interference (RNAi), a breakthrough that transformed genetic research and paved the way for RNA-based medicines. At the forum,
More news about: GenScript Biotech Corporation
Sep 24, 2025, 07:30 ET Replicate Bioscience Announces Publication of Promising New Phase 1 Durability Data for Its srRNA Vaccine Candidate RBI-4000
List. About Replicate BioscienceReplicate Bioscience is a clinical-stage company amplifying the power of RNA therapeutics by pioneering its novel self-replicating RNA (srRNA) technology to overcome the shortcomings of existing mRNA approaches, with potential improvements in bioactivity,
More news about: Replicate Bioscience
Sep 23, 2025, 10:30 ET Nanoparticle Based Vaccines to Treat, Prevent Severe Allergic Reactions
Sept. 23, 2025 /PRNewswire/ -- A vaccine that uses lipid nanoparticles to deliver allergen-specific messenger RNA (mRNA) showed early positive results at managing severe allergies in tests involving mice, according to a study led by experts at Cincinnati Children's
More news about: Cincinnati Children's Hospital Medical Center
Sep 23, 2025, 08:42 ET Major Childhood Cancer Initiative Formed - Childhood Cancer Prevention Consortium to Focus on Reducing the Dramatic Rise in the Number of Children Diagnosed with Cancer
Elias Sayour, MD, PhD, Associate Professor of Neurosurgery, and Pediatrics, as well as Principal Investigator of the RNA Engineering Laboratory within the Preston A. Wells, Jr. Center for Brain Tumor Therapy and UF Brain Tumor Immunotherapy Program, who is involved with
More news about: PREP4Gold Childhood Cancer Organization
Sep 22, 2025, 21:41 ET GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea
Ministry of Food and Drug Safety (MFDS) in South Korea for a Phase 1 clinical trial of "GC4006A," its mRNA (messenger RNA) vaccine candidate for COVID-19.
More news about: GC Biopharma
Sep 22, 2025, 11:16 ET RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare Diseases, Oncology, and Advances in RNA Technologies | DataM Intelligence
self-amplifying RNA and small activating RNA platforms. Download Exclusive Sample Report: https://www.datamintelligence.com/download-sample/rna-based-therapies-market
More news about: DataM Intelligence 4 Market Research LLP
Sep 22, 2025, 07:00 ET Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater, New Jersey, Insmed has offices and research
More news about: Insmed Incorporated
Sep 19, 2025, 23:02 ET Proya Cosmetics gewinnt den IFSCC 2025 Top 10 Papers of Basic Research Award
Innsbruck (Österreich) und dem West China Hospital der Sichuan Universität zusammen. Durch die Kombination fortschrittlicher Methoden wie DNA/RNA-Tiefensequenzierung, computergestützte Biologie, KI-gestütztes Moleküldesign und virtuelles Screening baut Proya Cosmetics eine originelle Plattform für die
More news about: Proya Cosmetics
Sep 19, 2025, 15:15 ET Proya Cosmetics Wins IFSCC 2025 Top 10 Papers of Basic Research Award
Austria), and West China Hospital of Sichuan University. By combining advanced methods such as DNA/RNA deep sequencing, computational biology, AI-assisted molecular design, and virtual screening, Proya Cosmetics is building an original platform for anti-aging
More news about: Proya Cosmetics
Sep 19, 2025, 02:20 ET Tryngolza ® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
People living with FCS are sometimes unable to work, adding to the burden of disease. About TRYNGOLZA® (olezarsen) Trynglolza® is an RNA-targeted medicine designed to lower the body's production of apolipoprotein C-III, a protein produced in the liver that is a key regulator of triglyceride
More news about: Swedish Orphan Biovitrum AB
Sep 18, 2025, 17:05 ET Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic
More news about: Co-Diagnostics
Sep 18, 2025, 09:15 ET Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting
More news about: Illumina, Inc.
Sep 17, 2025, 17:09 ET MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.
founded in 2021, is a clinical-stage biotech company pioneering next-generation mRNA and lipid nanoparticle (LNP) technologies to expand the reach of RNA-based medicines. The company's proprietary Engineered Cell-targeted LNP (EnC-LNP) platform enables precise delivery of mRNA into non-antigen presenting
More news about: Shenzhen MagicRNA Biotech Co., Ltd.